Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position

Zinger Key Points
  • NPCE's RNS System provides a unique window into brain activity.
  • The company addresses a currently estimated ~$2 billion market opportunity, one analyst notes.

Cantor Fitzgerald initiated coverage on NeuroPace Inc NPCE, a commercial-stage medical device company focused on drug-resistant epilepsy treatment through the company's responsive neurostimulation device (RNS).

The analyst Ross Osborn initiates with an Overweight rating and a price target of $11.

He notes the company addresses a currently estimated ~$2 billion market opportunity based on the 1.2 million people living with drug-resistant epilepsy (DRE) in the U.S. (~one in three patients with epilepsy). 

The opportunity to expand indications also provides a strong TAM growth potential.

The analyst notes that the company's differentiated proprietary technology drives adoption. 

NPCE's RNS System provides a unique window into brain activity, compared to other neuromodulation technology, offering continuous brain activity monitoring, recognizing and responding to patient-specific seizure patterns, and recording ongoing intracranial electroencephalography data.

Cantor notes NPCE's shares are currently trading at 2.6x CY24E revenue versus high-growth MedTech peers at 3.3x, representing an attractive entry point.

Price Action: NPCE shares are up 1.15% at $7.83 on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsHealth CareInitiationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!